AERI on NASDAQ

Aerie Pharmaceuticals

Aerie Pharmaceuticals was an American clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates were once-daily therapies for lowering intraocular pressure with mechanisms to treat patients with glaucoma or ocular hypertension.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

Jan 1, 2005Founded1

Compare with Adaptimmune (United Kingdom), REGENXBIO Inc. or Ginkgo Bioworks, or pick any stock.

  • TickerAERI on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersDurham1
  • Websitewww.aeriepharma.com
  • Incorporated inDE4
  • Business address4301 Emperor Boulevard, Suite 400, Durham, Nc 277034
  • Filer categoryLarge accelerated filer4

See how the biggest companies compare on our leaderboards

Aerie Pharmaceuticals was an American clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates were once-daily therapies for lowering intraocular pressure with mechanisms to treat patients with glaucoma or ocular hypertension.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-23.9%Operating margin5
-38.5%Net margin5
133.5%Revenue growth, 20215
-$102.4MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue11¢$26.8M
  • Research and development31¢$75.8M
  • Selling, general and admin57¢$137.8M
  • Income tax0¢$593.0K

Out of $194.1M in revenue.5 The company lost money this year.

Financial statements

Revenue6785$194.1M in 2021
0$50.0M$100.0M$150.0M$200.0M2016: $0$020162017: $0$020172018: $24.2M$24.2M20182019: $69.9M$69.9M2019+189%2020: $83.1M$83.1M2020+19%2021: $194.1M$194.1M2021+134%
Operating income96785-$46.4M in 2021−38% since 2015
-$300.0M-$200.0M-$100.0M02015: -$75.1M-$75.1M20152016: -$96.9M-$96.9M2016+29%2017: -$145.7M-$145.7M2017+50%2018: -$209.7M-$209.7M2018+44%2019: -$187.5M-$187.5M2019−11%2020: -$155.7M-$155.7M2020−17%2021: -$46.4M-$46.4M2021−70%
Net income96785-$74.8M in 2021+1% since 2015
-$300.0M-$200.0M-$100.0M02015: -$74.4M-$74.4M20152016: -$99.1M-$99.1M2016+33%2017: -$145.1M-$145.1M2017+46%2018: -$232.6M-$232.6M2018+60%2019: -$199.6M-$199.6M2019−14%2020: -$183.1M-$183.1M2020−8%2021: -$74.8M-$74.8M2021−59%
Fiscal year2015201620172018201920202021
Revenue$06$07$24.2M8$69.9M5$83.1M5$194.1M5
Cost of revenue$06$06$641.0K8$4.8M5$25.3M5$26.8M5
Research and development$44.5M9$52.4M6$72.1M7$86.1M8$91.4M5$74.0M5$75.8M5
Selling, general and admin$30.6M9$34.7M6$56.9M7$120.6M8$138.4M5$137.2M5$137.8M5
Operating income-$75.1M9-$96.9M6-$145.7M7-$209.7M8-$187.5M5-$155.7M5-$46.4M5
Interest$2.5M10$2.5M10
Income tax$139.0K9$193.0K6-$1.8M7$3.0K8-$90.0K5$5.2M5$593.0K5
Net income-$74.4M9-$99.1M6-$145.1M7-$232.6M8-$199.6M5-$183.1M5-$74.8M5
Earnings per share-$4.395-$3.995-$1.615
Earnings per share (diluted)-$4.395-$3.995-$1.615

Compare Aerie Pharmaceuticals with another company

Timeline

  1. Oct 25, 2013Went public Listed on NASDAQ1
  2. Jan 1, 2005Founded Founded1

Recent filings

  1. Nov 21, 20228-K
  2. Nov 21, 20224 FORM 4 SUBMISSION
  3. Nov 21, 20224 FORM 4 SUBMISSION
  4. Nov 21, 20224 FORM 4 SUBMISSION
  5. Nov 21, 20224 FORM 4 SUBMISSION
  6. Nov 21, 20224 FORM 4 SUBMISSION
  7. Nov 21, 20224 FORM 4 SUBMISSION
  8. Nov 21, 20224 FORM 4 SUBMISSION
  9. Nov 21, 20224 FORM 4 SUBMISSION
  10. Nov 21, 20224 FORM 4 SUBMISSION
  11. Nov 21, 20224 FORM 4 SUBMISSION
  12. Nov 21, 20224 FORM 4 SUBMISSION
  13. Nov 18, 20228-K
  14. Nov 7, 20228-K
  15. Nov 4, 202210-Q

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10